Clinical trials: Schizophrenia or Schizoaffective Disorder
Schizophrenia, Schizoaffective
Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia
This preliminary, randomized, double-blind, placebo-controlled clinical trial will evaluate frontal gamma coherence neurofeedback in adults with schizophrenia.
- Trial name
- NCT07659938
- Testing
- Frontal gamma coherence neurofeedback
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BioSignal Solutions LLC
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Affective Psychosis, Bipolar, Mania
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
- Conditions
- Affective Psychosis, Bipolar, Mania, Manic-Depressive Psychosis
- Trial name
- NCT00454883
- Testing
- ziprasidone
- Volunteers
- 379 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
Bioavailability of LY03004 and Risperdal® Consta®
This study is to assess the bioavailability of LY03004 compared to Risperdal Consta as well as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with repeat injections
- Trial name
- NCT02091388
- Testing
- LY03004, Risperdal® Consta®
- Where
- 10 sites in United States
- Volunteers
- 108 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Schizoaffective Disorder
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to establish pharmacodynamics (PD), pharmacokinetics (PK), and adverse event (AE) profile of OPC-34712 administered to schizophrenic/schizoaffective subjects.
- Trial name
- NCT01423916
- Testing
- OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg)
- Where
- 8 sites in United States
- Volunteers
- 218 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.
- Trial name
- NCT00190749
- Testing
- olanzapine, risperidone
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorders
A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess the long-term efficacy of Olanzapine Pamoate (OP) Depot in patients diagnosed with schizophrenia or schizoaffective disorder.
- Trial name
- NCT01389908
- Testing
- olanzapine
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Shalvata Mental Health Center
Schizophrenia, Schizoaffective Disorder
Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia
The purpose of this study is to evaluate the safety of risperidone treatment in patients who are overweight and/or obese.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00511628
- Testing
- Risperidone
- Volunteers
- 1,717 people
- Sponsor
- Janssen-Cilag, S.A.
Patient Treated With Lithium, With Bipolar or Schizo-affective Disorder, Hospitalized in a Psychiatric Ward
Validation of the French Version of the Lithium Knowledge Test (LKT)
Lithium is a drug used to treat several psychiatric illnesses. This medication requires particular vigilance because it has a narrow therapeutic margin: the dose necessary to obtain an effective treatment is close to the toxic…
- Trial name
- LKT (NCT06033326)
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Lille